BRCA Mutations Treatment Market Analysis

Treatment Type (Surgery, Chemotherapy, Platinum Agents, PARP Inhibitors)

Chemotherapy segment is likely to hold more than 68% BRCA mutations treatment market share by 2036 because of the increasing uses of chemotherapy for the treatment of cancer. According to Cancer World’s statistics, in 2018, 9.8 million out of 17 million new cancer cases worldwide, whereas 57.7% required chemotherapy. By 2040, there will be 26 million new cases of cancer worldwide, of which 53% (15 million) or +5.2 million new cases from 2018 would require chemotherapy.

An aberrant state of cells known as cancer results in unchecked cell growth and aggressive malignancies that kill millions of people annually. Their knowledge of the disease is expanding rapidly due to our growing understanding of the molecular mechanism(s) behind its growth. This has resulted in the development of numerous novel therapeutic approaches and the subsequent testing of them.

Cancer Type (Breast Cancer, Ovarian Cancer)

By 2036, breast cancer segment is set to dominate over 80% BRCA mutations treatment market share owing to the rising prevalence of breast cancer globally. 2.3 million women worldwide had a breast cancer diagnosis in 2022, and 670,000 people died from the disease. All across the world, breast cancer influences women at all ages after puberty, however, its frequency increases with age.

Aging, obesity, heavy alcohol consumption, radiation exposure history, family history of breast cancer, reproductive history (including age at first pregnancy and menstruation onset), tobacco use, and postmenopausal hormone therapy are some of the factors that raise the risk of breast cancer. Other than age (over 40) and gender (female), women without any other known breast cancer risk factor account for around half of all cases of breast cancer.

Our in-depth analysis of the global BRCA mutations treatment market includes the following segments: